Association between Osteopontin and EGFR Expression with Clinicopathological Parameters in Hepatocellular Carcinoma

10.4077/CJP.2012.BAA082

Wen-Chiuan Tsai；Herng-Sheng Lee；Jong-Shiaw Jin；Hong-Wei Gao；Tai-Kuang Chao；Ann Chen；Shin Nieh；De-Chuan Chan；Fei-Ni Chang；Chih-Kung Lin

hepatocellular carcinoma ； immunohistochemistry ； osteopontin ； EGFR

The Chinese Journal of Physiology

55卷6期（2012 / 12 / 31）

412 - 420

英文

Osteopontin (OPN) and epidermal growth factor receptor (EGFR) are important factors associated with tumor progression, invasion and metastasis in humans. The aim of this study was to assess the correlation of OPN and EGFR expression with hepatocellular carcinoma (HCC) progression. Expression of OPN and EGFR was assessed by immunohistochemistry in 100 HCC specimens. Immunostaining scores (0 to 400) were calculated from the percentage of cells (0 to 100) at each immunostaining intensity and the immunostaining intensity (0 to 4). The average immunostaining score for OPN was correlated with tumor grade (56.1 for grade I, 104.6 for grade II, and 141.2 for grade III; P = 0.023) and T stage (58.6 for stage T1, 85.9 for stage T2, 126.8 for stage T3, and 189.1 for stage T4; P = 0.029). Similarly, the average immunostaining score for EGFR was correlated with tumor grade (80.5 for grade I, 142.1 for grade II, 230.6 for grade III; P = 0.011) and T stage (96.4 for stage T1, 135.5 for stage T2, 221.3 for stage T3, and 261.4 for stage T4; P = 0.026). In addition, OPN and EGFR immunostaining scores were also correlated with M, N, and AJCC stages. In conclusion, higher expression of OPN and EGFR is significantly associated with advanced histological grades, advanced pathological stages and poorer survival rates in HCC. OPN and EGFR may be used as novel biomarkers for diagnosis or monitoring of progression of hepatocellular carcinoma.

1. Lin, C.C.,Hwang, J.M.,Tsai, M.T.,Su, W.W.,Chen, L.M.,Lai, T.Y.,Hsu, H.H.,Yen, S.K.,Huang, C.Y.,Liu, J.Y.(2010).Protein kinase C alpha location and the expression of phospho-MEK and MDR1 in hepatitis virus-related hepatocellular carcinoma biopsies.Chinese J. Physiol.,53,112-118.
   連結：
2. Allgaier, H.P.,Deibert, P.,Olschewski, M.,Spamer, C.,Blum, U.,Gerok, W.,Blum, H.E.(1998).Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients.Int. J. Cancer,79,601-605.
3. Breuhahn, K.,Longerich, T.,Schirmacher, P.(2006).Dysregulation of growth factor signaling in human hepatocellular carcinoma.Oncogene,25,3787-3800.
4. Butler, W.T.(1995).Structural and functional domains of osteopontin.Ann. N. Y. Acad. Sci.,760,6-11.
5. Chambers, A.F.,Wilson, S.M.,Kerkvliet, N.,O'Malley, F.P.,Harris, J.F.,Casson, A.G.(1996).Osteopontin expression in lung cancer.Lung Cancer,15,311-323.
6. Chedid, A.,Mendenhall, C.L.,Moritz, T.E.(1999).The antigenic heterogeneity of the bile duct epithelium in alcoholic liver disease. VA Cooperative Study Group 275.Arch. Pathol. Lab. Med.,123,411-414.
7. Chen, R.X.,Xia, Y.H.,Cui, J.F.,Xue, T.C.,Ye, S.L.(2010).Osteopontin, a single marker for predicting the prognosis of patients with tumornode-metastasis stage I hepatocellular carcinoma after surgical resection.J. Gastroenterol. Hepatol.,25,1435-1442.
8. Chen, R.X.,Xia, Y.H.,Xue, T.C.,Ye, S.L.(2011).Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.Mol. Biol. Rep.,38,3671-3677.
9. Chen, W.S.,Lazar, C.S.,Poenie, M.,Tsien, R.Y.,Gill, G.N.,Rosenfeld, M.G.(1987).Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.Nature,328,820-823.
10. Denhardt, D.T.,Noda, M.(1998).Osteopontin expression and function: role in bone remodeling.J. Cell. Biochem.,72,92-102.
11. Gong, M.,Meng, L.,Jiang, B.,Zhang, J.,Yang, H.,Wu, J.,Shou, C.(2008).p37 from mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR.Mol. Cancer Ther.,7,530-537.
12. Hamilton, S.R.,Aaltonen, L.A.(2000).WHO classification of tumors of the digestive system.Lyon, France:IRAC.
13. Higashiyama, M.,Ito, T.,Tanaka, E.,Shimada, Y.(2007).Prognostic significance of osteopontin expression in human gastric carcinoma.Ann. Surg. Oncol.,14,3419-3427.
14. Hsia, C.C.,Axiotis, C.A.,Di Bisceglie, A.M.,Tabor, E.(1992).Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver.Cancer,70,1049-1056.
15. Hui, A.M.,Sakamoto, M.,Kanai, Y.,Ino, Y.,Gotoh, M.,Yokota, J.,Hirohashi, S.(1996).Inactivation of P16INK4 in hepatocellular carcinoma.Hepatology,24,575-579.
16. Hwang, S.M.,Lopez, C.A.,Heck, D.E.,Gardner, C.R.,Laskin, D.L.,Laskin, J.D.,Denhardt, D.T.(1994).Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells.J. Biol. Chem.,269,711-715.
17. Lam, J.S.,Belldegrun, A.S.,Figlin, R.A.(2004).Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy.Clin. Cancer Res.,10,6304S-6309S.
18. Liaw, L.,Skinner, M.P.,Raines, E.W.,Ross, R.,Cheresh, D.A.,Schwartz, S.M.,Giachelli, C.M.(1995).The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.J. Clin. Invest.,95,713-724.
19. Lin, F.,Li, Y.,Cao, J.,Fan, S.,Wen, J.,Zhu, G.,Du, H.,Liang, Y.(2011).Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.Mol. Biol. Rep.,38,5205-5210.
20. Liu, P.,Li, Z.,Zhu, M.,Sun, Y.,Li, Y.,Wang, H.,Duan, Y.(2010).Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma.J. Mater. Sci. Mater. Med.,21,551-556.
21. Lu, J.G.,Li, Y.,Li, L.,Kan, X.(2011).Overexpression of osteopontin and integrin αv in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis.J. Cancer Res. Clin. Oncol.,137,1613-1618.
22. Maier, T.,Laubender, R.P.,Sturm, R.A.,Klingenstein, A.,Korting, H.C.,Ruzicka, T.,Berking, C.(2012).Osteopontin expression in plasma of melanoma patients and in melanocytic tumours.J. Eur. Acad. Dermatol. Venereol.,26,1084-1091.
23. Matušan-Ilijaš, K.,Damante, G.,Fabbro, D.,DorƋević, G.,Hadžisejdić, I.,Grahovac, M.,Marić, I.,Spanjol, J.,Grahovac, B.,Jonjić, N.,Lučin, K.(2011).Osteopontin expression correlates with nuclear factor-κB activation and apoptosis downregulation in clear cell renal cell carcinoma.Pathol. Res. Pract.,207,104-110.
24. Mise, M.,Arii, S.,Higashituji, H.,Furutani, M.,Niwano, M.,Harada, T.,Ishigami, S.,Toda, Y.,Nakayama, H.,Fukumoto, M.,Fujita, J.,Imamura, M.(1996).Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor.Hepatology,23,455-464.
25. Monto, A.,Wright, T.L.(2001).The epidemiology and prevention of hepatocellular carcinoma.Semin. Oncol.,28,441-449.
26. Ng, I.O.,Lai, E.C.,Fan, S.T.,Ng, M.M.,So, M.K.(1995).Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients.Cancer,76,2443-2448.
27. Nzeako, U.C.,Goodman, Z.D.,Ishak, K.G.(1996).Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients.Am. J. Clin. Pathol.,105,65-75.
28. Pan, H.W.,Ou, Y.H.,Peng, S.Y.,Liu, S.H.,Lai, P.L.,Lee, P.H.,Sheu, J.C.,Chen, C.L.,Hsu, H.C.(2003).Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.Cancer,98,119-127.
29. Parkin, D.M.,Pisani, P.,Ferlay, J.(1990).Estimates of the worldwide incidence of 25 major cancers in 1990.Int. J. Cancer,80,827-841.
30. Patarca, R.,Saavedra, R.A.,Cantor, H.(1993).Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene.Crit. Rev. Immunol.,13,225-246.
31. Quaglia, A.,Bhattacharjya, S.,Dhillon, A.P.(2001).Limitations of the histopathological diagnosis and prognostic assessment of hepatocellular carcinoma.Histopathology,38,167-174.
32. Roberts, L.R.,Gores, G.J.(2005).Hepatocellular carcinoma: molecular pathways and new therapeutic targets.Semin. Liver Dis.,25,212-225.
33. Salomon, D.S.,Brandt, R.,Ciardiello, F.,Normanno, N.(1995).Epidermal growth factor-related peptides and their receptors in human malignancies.Crit. Rev. Oncol. Hematol.,19,183-232.
34. Scatena, M.,Almeida, M.,Chaisson, M.L.,Fausto, N.,Nicosia, R.F.,Giachelli, C.M.(1998).NF-κB mediates αvβ3 integrin-induced endothelial cell survival.J. Cell Biol.,141,1083-1093.
35. Schafer, D.F.,Sorrell, M.F.(1999).Hepatocellular carcinoma.Lancet,353,1253-1257.
36. Schiffer, E.,Housset, C.,Cacheux, W.,Wendum, D.,Desbois-Mouthon, C.,Rey, C.,Clergue, F.,Poupon, R.,Barbu, V.,Rosmorduc, O.(2005).Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.Hepatology,41,307-314.
37. Sieghart, W.,Wang, X.,Schmid, K.,Pinter, M.,König, F.,Bodingbauer, M.,Wrba, F.,Rasoul-Rockenschaub, S.,Peck-Radosavljevic, M.(2011).Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria.J. Hepatol.,54,89-97.
38. Suzuki, K.,Hayashi, N.,Miyamoto, Y.,Yamamoto, M.,Ohkawa, K.,Ito, Y.,Sasaki, Y.,Yamaguchi, Y.,Nakase, H.,Noda, K.,Enomoto, N.,Arai, K.,Yamada, Y.,Yoshihara, H.,Tujimura, T.,Kawano, K.,Yoshikawa, K.,Kamada, T.(1996).Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma.Cancer Res.,56,3004-3009.
39. Thalmann, G.N.,Sikes, R.A.,Devoll, R.E.,Kiefer, J.A.,Markwalder, R.,Klima, I.,Farach-Carson, C.M.,Studer, U.E.,Chung, L.W.(1999).Osteopontin: possible role in prostate cancer progression.Clin. Cancer Res.,5,2271-2277.
40. Trevisani, F.,D'Intino, P.E.,Grazi, G.L.,Caraceni, P.,Gasbarrini, A.,Colantoni, A.,Stefanini, G.F.,Mazziotti, A.,Gozzetti, G.,Gasbarrini, G.,Bernardi, M.(1996).Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients.Cancer,77,2223-2232.
41. Tuck, A.B.,Chambers, A.F.(2001).The role of osteopontin in breast cancer: clinical and experimental studies.J. Mammary Gland Biol. Neoplasia,6,419-429.
42. Vejchapipat, P.,Tangkijvanich, P.,Theamboonlers, A.,Chongsrisawat, V.,Chittmittrapap, S.,Poovorawan, Y.(2004).Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma.J. Gastroenterol.,39,1182-1188.
43. Wang, H.H.,Wang, X.W.,Tang, C.E.(2011).Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease.J. Cancer Res. Ther.,7,138-142.
44. Whittaker, S.,Marais, R.,Zhu, A.X.(2010).The role of signaling pathways in the development and treatment of hepatocellular carcinoma.Oncogene,29,4989-5005.
45. Xuan, J.W.,Hota, C.,Shigeyama, Y.,D'Errico, J.A.,Somerman, M.J.,Chambers, A.F.(1995).Site-directed mutagenesis of the arginineglycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.J. Cell. Biochem.,57,680-690.
46. Zwick, E.,Hackel, P.O.,Prenzel, N.,Ullrich, A.(1999).The EGF receptor as central transducer of heterologous signalling systems.Trends Pharmacol. Sci.,20,408-412.

1. Wang, Pei-Yu,Pai, Li-Mei,Lin, Yu-Hung,Lee, Yen-Hsien,Lee, Wei-Hao,Lee, Chien-Kuo,Chou, He-Yen(2014).Effects of RING-SH2Grb2, a Chimeric Protein Containing the E3 Ligase Domain of Cb1, on the EGFR Pathway.中國生理學雜誌,57(6),350-357.
2. Yang, Hui-Ju,Lee, Meng-Chih,Kao, Erl-Shyh,Hu, Chao-Chin,Cheng, Chun-Yuan(2014).Inhibitory Effects of Scutellarein on Proliferation of Human Lung Cancer A549 Cells through ERK and NFκB Mediated by the EGFR Pathway.中國生理學雜誌,57(4),182-187.